Table 1. Alterations detected in NSCLC patients (n=28).
| Patient | SNV | Allele Frequency |
Validation (Sequencing) | CNA | Validation (RT-PCR) | Fusion |
|---|---|---|---|---|---|---|
| LC1 | met(13)-met(15) | |||||
| LC2 | ||||||
| LC3 | ||||||
| LC4 | ||||||
| LC5 | ||||||
| LC6 | ||||||
| LC7 | CCND1 (CN=8.5) | Yes | ||||
| LC8 | PIK3CA-G546K | 8% | Sanger | FGFR1 (CN=5.5) | Yes | |
| LC9 | ||||||
| LC10 | ||||||
| LC11 | ||||||
| LC12 | BRAF-V600E | 37% | Sanger | N.E. | ||
| LC13 | ||||||
| LC14 | PIK3CA-C420R | 26% | ERBB2 (CN=8) | Yes | N.E. | |
| LC15 | NRAS-G61K | 40% | ||||
| LC16 | ||||||
| LC17 | ||||||
| LC18 | KRAS-G12D | 58% | Sanger | |||
| LC19 | fgfr3 (17)- tacc3(11) | |||||
| LC20 | KRAS-G12C | 13.5% | Sanger | |||
| LC21 | N.E. | |||||
| LC22 | ||||||
| LC23 | KRAS-G12D | Sanger | ||||
| LC24 | EGFR-L858R | 25% | ||||
| LC25 | EGFR-GLU746_ALA750DEL | 20% | ||||
| LC26 | met(13)-met(15) | |||||
| LC27 | ||||||
| LC28 |
N.E. – Non Evaluable.